We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Tumor Biomarker Panel Improves Identification of Candidates for Lung Cancer Screening

By LabMedica International staff writers
Posted on 17 Jan 2022
Print article
Image: A chest X-ray showing a tumor in the lung (marked by arrow) (Photo courtesy of Wikimedia Commons)
Image: A chest X-ray showing a tumor in the lung (marked by arrow) (Photo courtesy of Wikimedia Commons)
Use of a blood-based tumor biomarker panel in combination with modeling according to results of PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial) significantly improved risk assessment for lung cancer screening.

Investigators at the University of Texas M. D. Anderson Cancer Center (Houston, USA) hypothesized that a combination of a blood-based four-marker protein panel combined with the (PLCO)m2012 lung cancer prediction model would better identify individuals for lung cancer screening compared with current U.S. Preventive Services Task Force (USPSTF) criteria.

To test the hypothesis, the investigators carried out a validation study using PLCO Cancer Screening Trial data and biospecimens to evaluate the performance of a four-marker protein panel (4MP) consisting of (1) the precursor form of surfactant protein B, (2) cancer antigen 125, (3) carcinoembryonic antigen, and (4) cytokeratin-19 fragment and compared results to current USPSTF screening criteria.

The validation study included analysis of 1,299 blood samples collected from 552 individuals who developed lung cancer and 8,709 samples collected from 2,193 people who did not develop the disease. Results revealed that the 4MP alone yielded an area under the receiver operating characteristic curve of 0.79 for case sera collected within one year preceding diagnosis and 0.74 among the entire specimen set. The combined 4MP + PLCOm2012 model yielded an area under the receiver operating characteristic curve of 0.85 for case sera collected within one year preceding diagnosis. The benefit of the 4MP in the combined model resulted from improvement in sensitivity at high specificity. Compared with the USPSTF2021 criteria, the combined 4MP + PLCOm2012 model exhibited statistically significant improvements in sensitivity and specificity.

Among PLCO participants with a history of more than 10 smoking pack-years, the 4MP + PLCOm2012 model would have identified for annual screening 9.2% more lung cancer cases and would have reduced referral by 13.7% among non-cases compared with USPSTF2021 criteria.

“We recognize that a small percentage of people who are eligible for lung cancer screening through an annual low-dose CT scan are actually getting screening. Moreover, CT screening is not readily available in most countries. So, our goal, for many years, has been to develop a simple blood test that can be used first to determine need for screening and make screening for lung cancer that much more effective,” said senior author Dr. Samir M. Hanash, professor of clinical cancer prevention at the University of Texas M. D. Anderson Cancer Center. “Our study shows for the first time that a blood test could be useful to determine who may benefit from lung cancer screening. A blood test would identify people who could benefit from lung cancer screening but are not eligible today. Tens of millions of people worldwide could benefit from lung cancer screening. If you can improve screening eligibility by even 5%, that is incredibly impactful.”

The study was published in the January 7, 2022, online edition of the Journal of Clinical Oncology.

Related Links:
University of Texas M. D. Anderson Cancer Center

Automated ELISA-IFA-BLOT Processor AP 22
Gold Supplier
SARS-CoV-2 Antigen Rapid Test
RapiSafe SARS-CoV-2 Antigen Rapid Test (Professional use)
Modular Sequencing Workstation
Automated Hematology Analyzer
Celltac Alpha MEK-1301/1302

Print article



view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio Acquires ADx NeuroSciences to Speed Development of Neurodegenerative Diseases Diagnostic Tests

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.